Peringkat dalam Saham
#2737
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$70.50
Terakhir disinkronkan: 2025-11-14
Kapitalisasi Pasar
$7.33B
Perubahan (1 tahun)
116.32%
Perdagangan Metsera, Inc. (MTSR)
Harga MTSR dengan kapitalisasi pasar B
Kapitalisasi pasar dari Metsera, Inc.(MTSR)
Kapitalisasi Pasar: $7.33B
Per August 2026, Metsera, Inc. memiliki kapitalisasi pasar sebesar $7.33B. Ini menjadikan Metsera, Inc. sebagai perusahaan 2737th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Metsera, Inc. dari 2025 hingga 2026
MTSR dibandingkan dengan 5 teratas stocks paling populer
| Harga MTSR |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.152T
|
+70,202.62%
|
|
|
|
|
$4.537T
|
+61,804.95%
|
|
|
|
|
$4.163T
|
+56,704.78%
|
|
|
|
|
$3.642T
|
+49,597.70%
|
|
|
|
|
$2.805T
|
+38,168.52%
|
